Cargando…

Integrative Strategy of Testing Systems for Identification of Endocrine Disruptors Inducing Metabolic Disorders—An Introduction to the OBERON Project

Exposure to chemical substances that can produce endocrine disrupting effects represents one of the most critical public health threats nowadays. In line with the regulatory framework implemented within the European Union (EU) to reduce the levels of endocrine disruptors (EDs) for consumers, new and...

Descripción completa

Detalles Bibliográficos
Autores principales: Audouze, Karine, Sarigiannis, Denis, Alonso-Magdalena, Paloma, Brochot, Celine, Casas, Maribel, Vrijheid, Martine, Babin, Patrick J., Karakitsios, Spyros, Coumoul, Xavier, Barouki, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216143/
https://www.ncbi.nlm.nih.gov/pubmed/32340264
http://dx.doi.org/10.3390/ijms21082988
_version_ 1783532350772084736
author Audouze, Karine
Sarigiannis, Denis
Alonso-Magdalena, Paloma
Brochot, Celine
Casas, Maribel
Vrijheid, Martine
Babin, Patrick J.
Karakitsios, Spyros
Coumoul, Xavier
Barouki, Robert
author_facet Audouze, Karine
Sarigiannis, Denis
Alonso-Magdalena, Paloma
Brochot, Celine
Casas, Maribel
Vrijheid, Martine
Babin, Patrick J.
Karakitsios, Spyros
Coumoul, Xavier
Barouki, Robert
author_sort Audouze, Karine
collection PubMed
description Exposure to chemical substances that can produce endocrine disrupting effects represents one of the most critical public health threats nowadays. In line with the regulatory framework implemented within the European Union (EU) to reduce the levels of endocrine disruptors (EDs) for consumers, new and effective methods for ED testing are needed. The OBERON project will build an integrated testing strategy (ITS) to detect ED-related metabolic disorders by developing, improving and validating a battery of test systems. It will be based on the concept of an integrated approach for testing and assessment (IATA). OBERON will combine (1) experimental methods (in vitro, e.g., using 2D and 3D human-derived cells and tissues, and in vivo, i.e., using zebrafish at different stages), (2) high throughput omics technologies, (3) epidemiology and human biomonitoring studies and (4) advanced computational models (in silico and systems biology) on functional endpoints related to metabolism. Such interdisciplinary framework will help in deciphering EDs based on a mechanistic understanding of toxicity by providing and making available more effective alternative test methods relevant for human health that are in line with regulatory needs. Data generated in OBERON will also allow the development of novel adverse outcome pathways (AOPs). The assays will be pre-validated in order to select the test systems that will show acceptable performance in terms of relevance for the second step of the validation process, i.e., the inter-laboratory validation as ring tests. Therefore, the aim of the OBERON project is to support the organization for economic co-operation and development (OECD) conceptual framework for testing and assessment of single and/or mixture of EDs by developing specific assays not covered by the current tests, and to propose an IATA for ED-related metabolic disorder detection, which will be submitted to the Joint Research Center (JRC) and OECD community.
format Online
Article
Text
id pubmed-7216143
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72161432020-05-22 Integrative Strategy of Testing Systems for Identification of Endocrine Disruptors Inducing Metabolic Disorders—An Introduction to the OBERON Project Audouze, Karine Sarigiannis, Denis Alonso-Magdalena, Paloma Brochot, Celine Casas, Maribel Vrijheid, Martine Babin, Patrick J. Karakitsios, Spyros Coumoul, Xavier Barouki, Robert Int J Mol Sci Project Report Exposure to chemical substances that can produce endocrine disrupting effects represents one of the most critical public health threats nowadays. In line with the regulatory framework implemented within the European Union (EU) to reduce the levels of endocrine disruptors (EDs) for consumers, new and effective methods for ED testing are needed. The OBERON project will build an integrated testing strategy (ITS) to detect ED-related metabolic disorders by developing, improving and validating a battery of test systems. It will be based on the concept of an integrated approach for testing and assessment (IATA). OBERON will combine (1) experimental methods (in vitro, e.g., using 2D and 3D human-derived cells and tissues, and in vivo, i.e., using zebrafish at different stages), (2) high throughput omics technologies, (3) epidemiology and human biomonitoring studies and (4) advanced computational models (in silico and systems biology) on functional endpoints related to metabolism. Such interdisciplinary framework will help in deciphering EDs based on a mechanistic understanding of toxicity by providing and making available more effective alternative test methods relevant for human health that are in line with regulatory needs. Data generated in OBERON will also allow the development of novel adverse outcome pathways (AOPs). The assays will be pre-validated in order to select the test systems that will show acceptable performance in terms of relevance for the second step of the validation process, i.e., the inter-laboratory validation as ring tests. Therefore, the aim of the OBERON project is to support the organization for economic co-operation and development (OECD) conceptual framework for testing and assessment of single and/or mixture of EDs by developing specific assays not covered by the current tests, and to propose an IATA for ED-related metabolic disorder detection, which will be submitted to the Joint Research Center (JRC) and OECD community. MDPI 2020-04-23 /pmc/articles/PMC7216143/ /pubmed/32340264 http://dx.doi.org/10.3390/ijms21082988 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Project Report
Audouze, Karine
Sarigiannis, Denis
Alonso-Magdalena, Paloma
Brochot, Celine
Casas, Maribel
Vrijheid, Martine
Babin, Patrick J.
Karakitsios, Spyros
Coumoul, Xavier
Barouki, Robert
Integrative Strategy of Testing Systems for Identification of Endocrine Disruptors Inducing Metabolic Disorders—An Introduction to the OBERON Project
title Integrative Strategy of Testing Systems for Identification of Endocrine Disruptors Inducing Metabolic Disorders—An Introduction to the OBERON Project
title_full Integrative Strategy of Testing Systems for Identification of Endocrine Disruptors Inducing Metabolic Disorders—An Introduction to the OBERON Project
title_fullStr Integrative Strategy of Testing Systems for Identification of Endocrine Disruptors Inducing Metabolic Disorders—An Introduction to the OBERON Project
title_full_unstemmed Integrative Strategy of Testing Systems for Identification of Endocrine Disruptors Inducing Metabolic Disorders—An Introduction to the OBERON Project
title_short Integrative Strategy of Testing Systems for Identification of Endocrine Disruptors Inducing Metabolic Disorders—An Introduction to the OBERON Project
title_sort integrative strategy of testing systems for identification of endocrine disruptors inducing metabolic disorders—an introduction to the oberon project
topic Project Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216143/
https://www.ncbi.nlm.nih.gov/pubmed/32340264
http://dx.doi.org/10.3390/ijms21082988
work_keys_str_mv AT audouzekarine integrativestrategyoftestingsystemsforidentificationofendocrinedisruptorsinducingmetabolicdisordersanintroductiontotheoberonproject
AT sarigiannisdenis integrativestrategyoftestingsystemsforidentificationofendocrinedisruptorsinducingmetabolicdisordersanintroductiontotheoberonproject
AT alonsomagdalenapaloma integrativestrategyoftestingsystemsforidentificationofendocrinedisruptorsinducingmetabolicdisordersanintroductiontotheoberonproject
AT brochotceline integrativestrategyoftestingsystemsforidentificationofendocrinedisruptorsinducingmetabolicdisordersanintroductiontotheoberonproject
AT casasmaribel integrativestrategyoftestingsystemsforidentificationofendocrinedisruptorsinducingmetabolicdisordersanintroductiontotheoberonproject
AT vrijheidmartine integrativestrategyoftestingsystemsforidentificationofendocrinedisruptorsinducingmetabolicdisordersanintroductiontotheoberonproject
AT babinpatrickj integrativestrategyoftestingsystemsforidentificationofendocrinedisruptorsinducingmetabolicdisordersanintroductiontotheoberonproject
AT karakitsiosspyros integrativestrategyoftestingsystemsforidentificationofendocrinedisruptorsinducingmetabolicdisordersanintroductiontotheoberonproject
AT coumoulxavier integrativestrategyoftestingsystemsforidentificationofendocrinedisruptorsinducingmetabolicdisordersanintroductiontotheoberonproject
AT baroukirobert integrativestrategyoftestingsystemsforidentificationofendocrinedisruptorsinducingmetabolicdisordersanintroductiontotheoberonproject